Incyte (NASDAQ:INCY) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Incyte (NASDAQ:INCY) in a report released on Wednesday,Benzinga reports. They currently have a $135.00 price objective on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on INCY. The Goldman Sachs Group reissued a “neutral” rating and set a $90.00 price objective on shares of Incyte in a research report on Thursday, January 8th. Jefferies Financial Group lowered Incyte from a “buy” rating to a “hold” rating and lowered their target price for the company from $120.00 to $94.00 in a report on Monday, March 16th. Morgan Stanley set a $102.00 price target on Incyte in a research report on Wednesday, February 11th. Piper Sandler increased their price objective on Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Finally, Weiss Ratings downgraded shares of Incyte from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. Nine investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $104.89.

Incyte Stock Performance

NASDAQ:INCY opened at $92.23 on Wednesday. The firm has a market capitalization of $18.35 billion, a PE ratio of 14.39, a PEG ratio of 0.72 and a beta of 0.84. Incyte has a 1 year low of $53.56 and a 1 year high of $112.29. The company has a current ratio of 3.32, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. The firm’s fifty day simple moving average is $99.56 and its 200 day simple moving average is $96.94.

Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). Incyte had a return on equity of 26.34% and a net margin of 25.03%.The firm had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same period in the prior year, the firm earned $1.43 EPS. The firm’s revenue was up 27.8% on a year-over-year basis. On average, sell-side analysts anticipate that Incyte will post 4.86 EPS for the current year.

Insider Activity

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $94.24, for a total transaction of $1,759,178.08. Following the completion of the transaction, the insider owned 234,800 shares in the company, valued at $22,127,552. This trade represents a 7.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mohamed Khairie Issa sold 10,856 shares of Incyte stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the sale, the executive vice president directly owned 66,132 shares in the company, valued at $7,213,017.24. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 17.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Incyte

A number of hedge funds have recently modified their holdings of INCY. Harbor Capital Advisors Inc. bought a new position in shares of Incyte during the 3rd quarter worth approximately $26,000. Root Financial Partners LLC bought a new stake in Incyte in the third quarter valued at $28,000. Elyxium Wealth LLC acquired a new position in Incyte during the fourth quarter worth $28,000. Smithfield Trust Co raised its stake in Incyte by 135.0% during the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 162 shares in the last quarter. Finally, Quent Capital LLC bought a new position in shares of Incyte during the third quarter valued at $30,000. 96.97% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and lifted its price target to $135, signalling strong analyst conviction and providing notable upside potential relative to the current share level. Article Title
• Neutral Sentiment: Incyte announced executive leadership appointments — a corporate governance update that may be viewed positively if it strengthens execution but is unlikely to move fundamentals immediately. Incyte Announces Executive Leadership Appointments
• Neutral Sentiment: Coverage piece assessing Incyte’s valuation after mixed short-term returns and strong one‑year performance — useful context for investors but not a direct near-term catalyst. A Look At Incyte (INCY) Valuation
• Neutral Sentiment: Multiple reports flagged a “significant” rise in short interest for March, but published figures show zero shares and NaN changes — likely a data/reporting anomaly. Investors should treat the short-interest headlines cautiously and monitor clearer data from exchanges.
• Negative Sentiment: UBS cut its price target from $104 to $94 and moved to a “neutral” rating, which narrows perceived upside and can weigh on sentiment among more conservative investors. Article Title
• Neutral Sentiment: A sector competitor (Karyopharm) reported mixed Phase 3 trial data in myelofibrosis — a development that may shift sector sentiment or competitive positioning but has uncertain direct impact on Incyte’s pipeline. Karyopharm myeloma drug yields mixed data in myelofibrosis trial

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.